Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAFV600-mutant melanoma: an open-label, single arm, dual-centre, phase 2 clinical trial

The Lancet Oncology

Volumn 18, Issue 4, 2017, Pages 464-472

  Schreuer, Max ^a   Jansen, Yanina ^a   Planken, Simon ^a   Chevolet, Ines ^b   Seremet, Teofila ^a   Kruse, Vibeke ^b   Neyns, Bart ^a  

^a UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

^b GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; CREATINE KINASE; DABRAFENIB; TRAMETINIB; ANTINEOPLASTIC AGENT; B RAF KINASE; BRAF PROTEIN, HUMAN; IMIDAZOLE DERIVATIVE; MAP2K1 PROTEIN, HUMAN; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; OXIME; PROTEIN KINASE INHIBITOR; PYRIDONE DERIVATIVE; PYRIMIDINONE DERIVATIVE;

ABSENCE OF SIDE EFFECTS; ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTHRALGIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BELGIUM; CANCER GROWTH; CLINICAL ARTICLE; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DECREASED APPETITE; DIARRHEA; DRUG DOSE REDUCTION; DRUG TOLERABILITY; FATIGUE; FEMALE; FEVER; HEADACHE; HUMAN; HYPERKERATOSIS; MALE; MELANOMA; MYALGIA; NAUSEA; OPEN STUDY; OVERALL SURVIVAL; PANNICULITIS; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; RASH; SIDE EFFECT; SKIN PAPILLOMA; TREATMENT RESPONSE; VOMITING; ANTAGONISTS AND INHIBITORS; CANCER STAGING; DISEASE COURSE; FOLLOW UP; GENETICS; LYMPH NODE METASTASIS; MIDDLE AGED; MUTATION; PATHOLOGY; PROGNOSIS; SECONDARY; SKIN NEOPLASMS; SURVIVAL RATE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMIDAZOLES; LYMPHATIC METASTASIS; MALE; MAP KINASE KINASE 1; MELANOMA; MIDDLE AGED; MUTATION; NEOPLASM STAGING; OXIMES; PROGNOSIS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; PYRIDONES; PYRIMIDINONES; SKIN NEOPLASMS; SURVIVAL RATE;

EID: 85014266456     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(17)30171-7     Document Type: Article

References (41)

1. 1 Houben, R, Becker, JC, Kappel, A, et al. Constitutive activation of the Ras-Raf signaling pathway in metastatic melanoma is associated with poor prognosis. J Carcinog, 3, 2004, 6.
2. 2 Curtin, JA, Fridlyand, J, Kageshita, T, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med 353 (2005), 2135–2147.
3. 3 Davies, H, Bignell, GR, Cox, C, et al. Mutations of the BRAF gene in human cancer. Nature 417 (2002), 949–954.
4. 4 Chapman, PB, Hauschild, A, Robert, C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364 (2011), 2507–2516.
5. 5 Long, GV, Stroyakovskiy, D, Gogas, H, et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet 386 (2015), 444–451.
6. 6 Larkin, J, Ascierto, PA, Dreno, B, et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med 371 (2014), 1867–1876.
7. 7 Long, GV, Weber, JS, Infante, JR, et al. Overall survival and durable responses in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib combined with trametinib. J Clin Oncol 34 (2016), 871–878.
8. 8 Robert, C, Karaszewska, B, Schachter, J, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med 372 (2015), 30–39.
9. 9 Robert, C, Schachter, J, Long, GV, et al. pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 372 (2015), 2521–2532.
10. 10 Schreuer, MS, Chevolet, IL, Jansen, YJ, et al. Objective responses can be obtained by CTLA-4 inhibition in metastatic melanoma after BRAF inhibitor failure. Melanoma Res 25 (2015), 68–74.
11. 11 Weber, JS, D'Angelo, SP, Minor, D, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 16 (2015), 375–384.
12. 12 Hodi, FS, O'Day, SJ, McDermott, DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363 (2010), 711–723.
13. 13 Chan, MM, Haydu, LE, Menzies, AM, et al. The nature and management of metastatic melanoma after progression on BRAF inhibitors: effects of extended BRAF inhibition. Cancer 120 (2014), 3142–3153.
14. 14 Oudard, S, Geoffrois, L, Guillot, A, et al. Clinical activity of sunitinib rechallenge in metastatic renal cell carcinoma—results of the rechallenge with sunitinib in metastatic RCC (RESUME) study. Eur J Cancer 62 (2016), 28–35.
15. 15 Kang, YK, Ryu, MH, Yoo, C, et al. Resumption of imatinib to control metastatic or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib (RIGHT): a randomised, placebo-controlled, phase 3 trial. Lancet Oncol 14 (2013), 1175–1182.
16. 16 Welsh, SJ, Rizos, H, Scolyer, RA, Long, GV, Resistance to combination BRAF and MEK inhibition in metastatic melanoma: where to next?. Eur J Cancer 62 (2016), 76–85.
17. 17 Yu, HA, Arcila, ME, Rekhtman, N, et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res 19 (2013), 2240–2247.
18. 18 Soverini, S, Colarossi, S, Gnani, A, et al. Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia. Clin Cancer Res 12 (2006), 7374–7379.
19. 19 Nazarian, R, Shi, H, Wang, Q, et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 468 (2010), 973–977.
20. 20 Johnson, DB, Menzies, AM, Zimmer, L, et al. Acquired BRAF inhibitor resistance: a multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms. Eur J Cancer 51 (2015), 2792–2799.
21. 21 Sun, C, Wang, L, Huang, S, et al. Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma. Nature 508 (2014), 118–122.
22. 22 Roux, J, Pages, C, Malouf, D, et al. BRAF inhibitor rechallenge in patients with advanced BRAF V600-mutant melanoma. Melanoma Res 25 (2015), 559–563.
23. 23 Seghers, AC, Wilgenhof, S, Lebbe, C, Neyns, B, Successful rechallenge in two patients with BRAF-V600-mutant melanoma who experienced previous progression during treatment with a selective BRAF inhibitor. Melanoma Res 22 (2012), 466–472.
24. 24 Romano, E, Pradervand, S, Paillusson, A, et al. Identification of multiple mechanisms of resistance to vemurafenib in a patient with BRAFV600E-mutated cutaneous melanoma successfully rechallenged after progression. Clin Cancer Res 19 (2013), 5749–5757.
25. 25 Schreuer, M, Meersseman, G, Van Den Herrewegen, S, et al. Quantitative assessment of BRAF V600 mutant circulating cell-free tumor DNA as a tool for therapeutic monitoring in metastatic melanoma patients treated with BRAF/MEK inhibitors. J Transl Med, 14, 2016, 95.
26. 26 Janku, F, Angenendt, P, Tsimberidou, AM, et al. Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies. Oncotarget 6 (2015), 12809–12821.
27. 27 Oxnard, GR, Paweletz, CP, Kuang, YA, et al. Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA. Clin Cancer Res 20 (2014), 1698–1705.
28. 28 Eisenhauer, EA, Therasse, P, Bogaerts, J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45 (2009), 228–247.
29. 29 Wolchok, JD, Hoos, A, O'Day, S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 15 (2009), 7412–7420.
30. 30 Wilgenhof, S, Corthals, J, Heirman, C, et al. Phase II study of autologous monocyte-derived mRNA elecetroporated dendritic cells (TriMixDC-MEL) plus ipilimumab in patients with pretreated advanced melanoma. J Clin Oncol 34 (2016), 1330–1338.
31. 31 Kim, KB, Kefford, R, Pavlick, AC, et al. Phase II study of the MEK1/MEK2 inhibitor trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. J Clin Oncol 31 (2013), 482–489.
32. 32 Johnson, DB, Flaherty, KT, Weber, JS, et al. Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor. J Clin Oncol 32 (2014), 3697–3704.
33. 33 Chen, G, McQuade, JL, Panka, DJ, et al. Clinical, molecular, and immune analysis of dabrafenib-trametinib combination treatment for BRAF inhibitor-refractory metastatic melanoma: a phase 2 clinical trial. JAMA Oncol 2 (2016), 1056–1064.
34. 34 Girotti, MR, Pedersen, M, Sanchez-Laorden, B, et al. Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma. Cancer Discov 3 (2013), 158–167.
35. 35 Frederick, DT, Piris, A, Cogdill, AP, et al. BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin Cancer Res 19 (2013), 1225–1231.
36. 36 Wilmott, JS, Long, GV, Howle, JR, et al. Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma. Clin Cancer Res 18 (2012), 1386–1394.
37. 37 Ribas, A, Puzanov, I, Dummer, R, et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol 16 (2015), 908–918.
38. 38 Ribas, A, Hodi, FS, Callahan, M, Konto, C, Wolchok, J, Hepatotoxicity with combination of vemurafenib and ipilimumab. N Engl J Med 368 (2013), 1365–1366.
39. 39 Minor, DR, Puzanov, I, Callahan, MK, Hug, BA, Hoos, A, Severe gastrointestinal toxicity with administration of trametinib in combination with dabrafenib and ipilimumab. Pigment Cell Melanoma Res 28 (2015), 611–612.
40. 40 Sanmamed, MF, Fernandez-Landazuri, S, Rodriguez, C, et al. Quantitative cell-free circulating BRAFV600E mutation analysis by use of droplet digital PCR in the follow-up of patients with melanoma being treated with BRAF inhibitors. Clin Chem 61 (2015), 297–304.
41. 41 Santiago-Walker, A, Gagnon, R, Mazumdar, J, et al. Correlation of BRAF mutation status in circulating-free DNA and tumor and association with clinical outcome across four BRAFi and MEKi clinical trials. Clin Cancer Res 22 (2016), 567–574.